Speech by Federal Chancellor Dr. Angela Merkel at the celebration "150 Years of Bayer" on July 16, 2013, in Cologne:

Germany Angela Merkel · Former Chancellor of Germany

16 July 2013 · Celebration "150 Years of Bayer" · Cologne, Germany

Context
Merkel addressed Bayer AG's 150th anniversary celebration on July 16, 2013, in Cologne, praising the company's innovation legacy and Germany's industrial future.
Main themes
Bayer AG 150th anniversary, innovation and research, German chemical and pharmaceutical industry, quality of life, energy transition and competitive energy prices, healthcare and demographic change, entrepreneurial spirit, raw materials strategy, industrial competitiveness, chemistry in everyday life
Duration
~17 min
57th percentile
Words
1,997
57th percentile
Sentences
128
74th percentile
Readability
45
48th percentile
Grade
10.8
30th percentile
Syntax
2.77
18th percentile
Vocabulary
2.04
17th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 39%39%
  • Social 34%34%
  • Ceremonial 9%9%
  • Technological 7%7%
  • Institutional 7%7%
  • Environmental 2%2%
  • Geopolitical 2%2%
  • Not in focus 1%

128 sentences in 25 paragraphs

Dear Mr. Dekkers,

dear Mr. Wenning,

dear Minister-President, dear Ms. Kraft,

ladies and gentlemen,

dear employees of Bayer,

the name Bayer has a firm place in the history of German industry. 150 years of Bayer – congratulations. The name Bayer stands for entrepreneurial spirit. Today, reference has already been made to Friedrich Bayer and Johann Friedrich Weskott, who at their time in Wuppertal-Barmen certainly did not suspect that from their kitchen production, 150 years later, a company with 110,000 employees worldwide, of which 35,000 are in Germany, would emerge. The name Bayer stands for success. The small dye factory has gradually outgrown its infancy, established itself at the new location in Leverkusen, increasingly expanded abroad; and new business areas were continually added. Today, the corporation employs 110,000 people and generates nearly 40 billion euros in revenue. The ink with which this success story was written is innovation. Bayer invested around three billion euros in research and development alone last year. This is an increase compared to the previous year.

The history of the company is a story of change, renewal, and curiosity. Its last major restructuring was only a few years ago. Since then, the areas of health and agriculture have become increasingly important in the corporate portfolio. Together with the business area of material development, you have three central engines that drive your work for a better quality of life worldwide. "Science for a better life" – that is your English motto. This is how you describe your corporate mission. This is also the central message of your company logo – the legendary Bayer cross. You are addressing many of the great challenges of our time – we just saw that again in the film – whether it is health and nutrition, mobility, safety, and communication. All of these are areas that touch the quality of life of people worldwide.

That is why I say: The chemical industry must remain firmly rooted in Germany in the future. Today, one is sometimes asked: What do you think of chemistry; do you want a life with chemistry? When I look surprised and say, "Can you exist without chemistry?", I usually get the answer after some thought that humans indeed have a lot to do with chemistry. This means that a life without chemistry is not possible. With this insight, much would already be gained. Then, in some places, the love for chemistry might grow a little stronger again. Germany and chemistry belong together.

I believe that new challenges also create new opportunities – for example, in the area of energy and resource efficiency. As a federal government, we have developed a raw materials strategy. Energy efficiency plays a central role in the energy transition. Of course, for a chemical company, the issue of energy prices is also a central topic, especially in light of global developments such as those in the United States. We need reasonable, competitive energy prices, especially for our industrial value creation. Therefore – I spoke about this with the Minister-President before this event – we will also fight decisively in Brussels to ensure that the exemptions for energy-intensive industries remain valid, as they are a prerequisite for global competitiveness.

We want you to continue your successful work as a driver of innovation. Today's innovations are changing the world of tomorrow. Often, one is not even aware – Mr. Dekkers mentioned it – of the long groundwork on which visible innovations are based. This applies to medicine, and it also applies to many other innovations. Inherent in innovation is always the question: Will it be a success or not? This means that if we want to remain innovative, we must also always be prepared for the fact that some innovations may not reach their goals, and thus follow-up innovations may not be able to emerge. Great expectations have always been placed on chemistry in connection with innovations. The physician and alchemist Paracelsus is said to have stated: "The true purpose of chemistry is not to make gold, but to produce medicine." In this regard, Bayer has proven to be a gold mine. Many medications – aspirin has already been mentioned – have shaped your reputation. And I hope that many more health developments and medications will also shape Bayer's future.

Germany is a leader in healthcare. In a global comparison, we have a good level. But in light of demographic change, the challenges in this area will also increase for the Federal Republic of Germany. That is why we have made various political adjustments. We have reorganized the financial basis of our healthcare system. We have improved the structures for providing medical care as close to home as possible – yet there is still much to be done in the coming years. And we have set incentives to achieve better quality in healthcare.

Of course, the pharmaceutical industry also contributes to improving healthcare. But it must also contribute to keeping the costs of our healthcare system manageable. In this field, we are indeed having critical or controversial discussions. I want to assure you that we want to conduct these discussions in a spirit that continues to provide a home for innovative medicine in Germany. This also repeatedly involves therapeutic added value. However, I know that patented medications are based on long development periods. If we want to remain an attractive location for the pharmaceutical industry, we must not only accept this but also take it into account and make patent development possible.

The federal government has launched a framework program for health research. This particularly focuses on improving prevention, diagnosis, and therapy for major common diseases. I believe that successful location policy will increasingly require an intertwining of economic, research, and health policy in the future. Therefore, we are also working across departments in the federal government. The health economy conference, jointly organized by the Federal Minister of Health and the Federal Minister of Economics, is an expression of this. We know from many other countries around the world that such integrative approaches are also being chosen there.

Forces must be pooled when it comes not only to health but also to other existential questions, such as food security. The number of people worldwide will continue to increase – from currently seven billion to approximately nine billion by 2050. Therefore, agricultural productivity is a key question for food security. Bayer is addressing these challenges. Your CropScience division invests in plant protection, plant breeding, and plant traits. In doing so, you are shaping the agriculture of the future. This is, globally speaking, a very important field, especially when following the discussions in many countries around the world. Therefore, the federal government is directing its gaze to the future with its "National Research Strategy Bioeconomy 2030." We want to create suitable framework conditions so that innovation in this area can also take place in Germany.

In all the challenges we face, we do not rely on the principle of hope, but on new ideas and new inventions. Knowledge is Germany's most important resource in global competition. Knowledge creates prosperity. That is why education and research are central building blocks of a future-oriented policy. We have increased spending on education and research by over 13 billion euros in this legislative period. This is the largest increase ever in the history of the Federal Republic of Germany. But this is also necessary when I look at how other countries invest in these areas.

Good education and qualification are prerequisites for successful research and innovation. That is why we have jointly increased the funds for the higher education pact with the states. This will create an additional 300,000 study places. But we are not only concerned with quantity; we are also focused on quality. That is why there is also a quality pact for teaching, which promotes innovative teaching approaches.

I would also like to emphasize once again what the Minister-President said: In all the promotion of higher education, the second pillar of our vocational education system, namely dual training, must also be strengthened. I would like to thank Bayer in this context. Bayer makes a significant contribution to the success of the training pact. The dual training system is currently gaining a good reputation worldwide. For this reason, it will also be important that we continue to nurture, maintain, and further develop it in Germany.

I would also like to thank you for Bayer's involvement in many projects. The school program has already been mentioned. It is good when young people in many other countries are inspired by Bayer to pursue the sciences. This is a long-term or slowly developing process. For me, there was not one moment of ignition, but the joy of science developed slowly – also through good teachers, exciting lectures, and interesting phenomena that one could eventually explain. This is not so easy, for example, with a rainbow. Therefore, I am pleased that the "Youth Research" project is also supported by Bayer. You have already taken on the sponsorship of this nationwide idea competition for the fourth time. Thank you very much for that.

It is important that young people are inspired early on for the so-called STEM subjects. This applies to boys, but even more so to girls, who are still underrepresented in these subjects. When I think of my annual reception on "Girls' Day" and ask the young girls about their career aspirations, I see that they can indeed be inspired even more for the entire STEM field.

We have finally succeeded in better recognizing foreign professional qualifications – this took many years in Germany. Since the introduction of the Blue Card, Germany's reputation as a country that welcomes skilled workers could also improve.

We are therefore working on the framework conditions under which you at Bayer and other companies can compete in the global market. We are also improving the framework conditions at the European level. We know that Europe must do well for Germany to do well in the long term. That is why we are doing everything to stabilize the euro.

We also see the negotiations for a transatlantic free trade agreement to create a free trade zone between the United States and Europe as an important project to open up new growth opportunities.

However, I must also say in light of the current discussion that opportunities must be utilized in all directions. The digital age brings completely new challenges. Therefore, the issue of data protection must also play a central role in these discussions. Freedom and security must always be kept in balance, even in an increasingly open world. I am equally committed to protecting citizens from terrorism as I am to protecting citizens' privacy. The end does not justify the means. I also want to say to our American partners: On German soil, German law always applies; and we will demand that.

The chemical industry, with its more than 400,000 employees, is one of the great pillars of German industry. This is also because companies like Bayer understand sustainability as a corporate success strategy. Economic performance, social responsibility – especially within the framework of collective bargaining – and the protection of natural living conditions are mutually dependent. You at Bayer not only know this, but you also act accordingly. Sustainability requires the ability to think long-term, to take into account the quality of life and prosperity of tomorrow today. A company that can look back on a 150-year history also looks far into the future.

Therefore, in conclusion, I would like to express my heartfelt thanks once again for Bayer being what it is today with its Bayer cross: a widely shining emblem of Germany. I wish you much success in ensuring that Bayer remains that way – Bayer as a symbol of the innovation and high-tech location of Germany, a company with secure and good jobs, with a good community of management and employees, as well as with exciting challenges that you are eager to take on.